Development of a succinyl CoA:3-ketoacid CoA transferase inhibitor selective for peripheral tissues that improves glycemia in obesity.

Of interest, PSSI-51 treatment showed a trend toward increasing brain ketone oxidation, which is compatible with systemic SCOT inhibition increasing circulating ketone levels ( Figure 3 B) and subsequent brain exposure.

also in 53,322 other papers